En­do sues Zy­dus in patent bat­tle over meth­ods of pu­ri­fy­ing gener­ic ver­sion of re­called smok­ing ces­sa­tion drug Chan­tix

En­do In­ter­na­tion­al, which lost a patent bat­tle last year over its va­so­pressin in­jec­tion Va­sostrict, is back in court — this time su­ing Zy­dus Phar­ma­ceu­ti­cals for patent in­fringe­ment over its gener­ic ver­sion of Pfiz­er’s smok­ing-ces­sa­tion drug Chan­tix.

En­do’s gener­ic drug mak­ing sub­sidiary Par Phar­ma­ceu­ti­cal filed its com­plaint on Aug. 8 in Delaware Dis­trict Court against Zy­dus, al­leg­ing that Zy­dus’ gener­ic in­fringes on En­do’s re­cent­ly-filed patent for how to pu­ri­fy the drug. En­do has al­so asked for an un­spec­i­fied amount of dam­ages and that Zy­dus’ gener­ic be tak­en off of the mar­ket.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER